Invitae Reproductive Health
→
Natera
Asset Acquisition · Cash (asset acquisition) · NTRA · announced Jan 22, 2024
Announced
Jan 22, 2024
Closed
Jan 22, 2024
Economics
Cash (asset acquisition)()
Pre-deal · pre-deal mark: 2024, year precision · Natera 8-K filing, SEC EDGAR — Invitae asset acquisition
$10M upfront + up to $42.5M milestones (cash + litigation credits)
Target
Invitae Reproductive Health
Diagnostics · Diagnostic / genomic
HQ San Francisco, CA · Founded 2012
Non-invasive prenatal screening (NIPS) and carrier screening business — divested reproductive health assets from Invitae's broader genetic testing portfolio
- Business Wire — Natera press release (Jan 22, 2024)
- Natera investor relations
Acquirer
Natera (NTRA)
Diagnostics
HQ Austin, TX
Why this buyer
Curated copy from the verified dataset — not an 8-K LLM summary
Acquired Invitae's NIPS and carrier screening customers — consolidates prenatal/reproductive cfDNA testing market under Natera's platform
Evidence ladder
Secondary (press / IR)
Business Wire — Natera press release (Jan 22, 2024)
Limitations
- Single-source or weak corroboration — treat valuation and timing as directional.
- $10M upfront + up to $42.5M milestones (cash + litigation credits)
- Pre-deal valuation sourced from: Natera 8-K filing, SEC EDGAR — Invitae asset acquisition. Pre-deal market-cap and funding citations do not corroborate the acquisition.
Valuation peers · Diagnostics
Same sector, same deal type, announced within ±3 years, disclosed value within 0.25×–4× of this transaction. Ranked by evidence class, then same acquirer, until you sort.
Insufficient disclosed data
No verified Diagnostics deals meet the peer rule: same deal type, announced within ±3 years, and a disclosed value inside 0.25×–4× of this transaction.
Same-sector adjacency — not valuation peers
These deals share the sector tag and window but sit outside the 0.25×–4× value band. The dataset keeps them for clinical adjacency, not as price comps.
| Vs this deal | ||||
|---|---|---|---|---|
| BioReference Health (clinical, women's health, urology and 4Kscore assets) | LabCorp | Oct 15, 2026 | ||
| BioReference Health (clinical diagnostics and reproductive & women's health, outside NY/NJ) | LabCorp | Mar 28, 2024 |
Other verified deals by Natera
Acquirer program history not already listed as a valuation peer or adjacency row.
No further verified deals
Other verified transactions by Natera are already listed above, or none are in the dataset.
Patient empowerment context
Empowerment context — Invitae Reproductive Health
Curated survey mappingHLTH/Outcomes4Me 2022 surveyed breast cancer patients (n=1,828). Breast cancer care continuum (HLTH 2022). Rows below are analyst-curated mappings to cited survey items — not live patient outcomes for this target.
- Not recommended genetic testing (NCCN: almost all should)37%cited HLTH 2022
Other curated mappings on these gaps: Biotheranostics, Endomagnetics, Genomic Health, Foundation Medicine
Full cited gap matrix →Related verified workspaces
Lacuna is a curated public-source sample, not a census of women's-health M&A. Coverage varies by sector, geography, disclosure availability, and women's-health scope. Undisclosed transaction values are excluded from disclosed-value totals.
Curated verified dataset v11 · updated 2026-10-19 · 1 citations on this deal · Data compiled from public sources for educational visualization. Verify independently before any commercial use.